WO1998027227B1 - Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux - Google Patents
Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveuxInfo
- Publication number
- WO1998027227B1 WO1998027227B1 PCT/IB1997/001648 IB9701648W WO9827227B1 WO 1998027227 B1 WO1998027227 B1 WO 1998027227B1 IB 9701648 W IB9701648 W IB 9701648W WO 9827227 B1 WO9827227 B1 WO 9827227B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- disease
- diagnosed
- allele
- phenotyping
- Prior art date
Links
- 230000002974 pharmacogenomic Effects 0.000 title claims 2
- 208000009025 Nervous System Disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract 11
- 230000000926 neurological Effects 0.000 claims abstract 7
- 238000004393 prognosis Methods 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims abstract 4
- 229940079593 drugs Drugs 0.000 claims abstract 4
- 101700025839 APOE Proteins 0.000 claims 5
- 101700070309 apoeb Proteins 0.000 claims 5
- 230000000718 cholinopositive Effects 0.000 claims 4
- 210000000653 nervous system Anatomy 0.000 claims 3
- 102000013918 Apolipoproteins E Human genes 0.000 claims 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims 2
- 208000009905 Neurofibromatosis Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 208000003055 Prion Disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000002475 cognitive enhancer Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 108009000447 Amino Acid metabolism Proteins 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 206010007654 Cardiovascular injury Diseases 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 208000001590 Congenital Abnormality Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000001914 Fragile X Syndrome Diseases 0.000 claims 1
- 108009000484 Fragile X Syndrome Proteins 0.000 claims 1
- 208000004776 Gamma-cystathionase deficiency Diseases 0.000 claims 1
- 208000006599 Histidinemia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020365 Homocystinuria Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010020575 Hyperammonaemia Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 101710024107 PRNP Proteins 0.000 claims 1
- 102000033170 PRNP Human genes 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000011585 Pick's disease Diseases 0.000 claims 1
- 102000015499 Presenilins Human genes 0.000 claims 1
- 108010050254 Presenilins Proteins 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000037354 amino acid metabolism Effects 0.000 claims 1
- 201000003554 argininosuccinic aciduria Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000004051 cystathioninuria Diseases 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary Effects 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000011240 frontotemporal dementia Diseases 0.000 claims 1
- 201000011252 phenylketonuria Diseases 0.000 claims 1
- 201000011296 tyrosinemia Diseases 0.000 claims 1
- 229940121657 Clinical Drug Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Abstract
La présente invention se rapporte à un procédé permettant de diagnostiquer une maladie neurologique et d'établir la thérapie adaptée à un patient chez qui l'on a diagnostiqué une telle maladie. La présente invention se rapporte également à un procédé d'identification de sujets humains sélectionnés pour subir des essais cliniques de médicaments dont on vérifie l'aptitude à traiter des maladies neurologiques.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56757/98A AU745073B2 (en) | 1996-12-16 | 1997-12-16 | Pharmacogenetic methods for use in the treatment of nervous system diseases |
CA002275504A CA2275504C (fr) | 1996-12-16 | 1997-12-16 | Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux |
DE69729473T DE69729473T2 (de) | 1996-12-16 | 1997-12-16 | Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems |
EP97953011A EP0946753B1 (fr) | 1996-12-16 | 1997-12-16 | Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux |
JP52750798A JP2001524809A (ja) | 1996-12-16 | 1997-12-16 | 神経系疾患の治療に使用するための遺伝薬理学的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/766,975 | 1996-12-16 | ||
US08/766,975 US6022683A (en) | 1996-12-16 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998027227A2 WO1998027227A2 (fr) | 1998-06-25 |
WO1998027227A3 WO1998027227A3 (fr) | 1998-08-27 |
WO1998027227B1 true WO1998027227B1 (fr) | 1998-10-15 |
Family
ID=25078098
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1997/001648 WO1998027227A2 (fr) | 1996-12-16 | 1997-12-16 | Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux |
PCT/IB1997/001641 WO1998027226A2 (fr) | 1996-12-16 | 1997-12-16 | Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1997/001641 WO1998027226A2 (fr) | 1996-12-16 | 1997-12-16 | Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique |
Country Status (8)
Country | Link |
---|---|
US (2) | US6022683A (fr) |
EP (2) | EP0948647B1 (fr) |
JP (4) | JP2001524809A (fr) |
AT (1) | ATE269978T1 (fr) |
AU (2) | AU745073B2 (fr) |
CA (2) | CA2275504C (fr) |
DE (2) | DE69729654T2 (fr) |
WO (2) | WO1998027227A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US6441149B1 (en) | 1998-06-15 | 2002-08-27 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
US6489095B2 (en) | 1998-06-15 | 2002-12-03 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
US6218117B1 (en) | 1998-06-15 | 2001-04-17 | Mitokor | Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios |
CA2330829C (fr) * | 1998-06-16 | 2011-08-02 | Nova Molecular, Inc. | Procedes relatifs au traitement d'une maladie neurologique par determination du genotype de butyrylcholinesterase (bche) |
AU773765B2 (en) | 1998-10-01 | 2004-06-03 | Variagenics, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele |
WO2000070340A2 (fr) * | 1999-05-14 | 2000-11-23 | Karolinska Innovations Ab | Materiaux et procedes se rapportant au diagnostic de maladie |
EP1208421A4 (fr) * | 1999-06-25 | 2004-10-20 | Genaissance Pharmaceuticals | Obtention et utilisation de donnees sur les haplotypes |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
US6896881B1 (en) | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
WO2001069261A2 (fr) * | 2000-03-15 | 2001-09-20 | Oxford Glycosciences (Uk) Ltd. | Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
ES2323940T3 (es) * | 2000-05-01 | 2009-07-28 | Accera, Inc. | Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer. |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US20040106124A1 (en) * | 2001-02-12 | 2004-06-03 | Murphy Greer M. | Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4 |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
GB0106051D0 (en) * | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
AU2002363329A1 (en) * | 2001-11-06 | 2003-05-19 | Elizabeth Gray | Pharmacogenomics-based system for clinical applications |
CN1612936A (zh) | 2001-11-09 | 2005-05-04 | 苏尔斯精细医药公司 | 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态 |
US20030224446A1 (en) * | 2001-12-20 | 2003-12-04 | Harry G. Jean | Method of predicting cytokine response to tissue injury |
US20040267458A1 (en) * | 2001-12-21 | 2004-12-30 | Judson Richard S. | Methods for obtaining and using haplotype data |
AU2003216186A1 (en) * | 2002-02-14 | 2003-09-04 | Medavante, Inc. | System and method for facilitating candidate and subject participation in clinical trial studies |
US7432355B2 (en) * | 2002-08-09 | 2008-10-07 | The J. David Gladstone Institutes | Apolipoprotein E stable folding intermediate and methods of use thereof |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
WO2004111652A1 (fr) * | 2003-06-19 | 2004-12-23 | Applied Research Systems Ars Holding N.V. | Utilisation d'agents modulateurs de la conversion de prions |
US20050038692A1 (en) * | 2003-08-14 | 2005-02-17 | Kane John Michael | System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies |
ZA200605829B (en) * | 2004-01-16 | 2007-11-28 | Disease Man Services Plc | Disease Management System |
US8466144B2 (en) | 2004-07-16 | 2013-06-18 | Proteosys Ag | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
US20070135376A1 (en) * | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
EP2508621B1 (fr) * | 2005-11-29 | 2014-11-05 | Children's Hospital Medical Center | Optimisation et personnalisation de selection et de sosage de medicaments |
HUE040002T2 (hu) * | 2006-04-03 | 2019-02-28 | Accera Inc | Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére |
US20080126118A1 (en) * | 2006-11-24 | 2008-05-29 | General Electric Company, A New York Corporation | Systems, methods and apparatus for a network application framework system |
TWI362012B (en) * | 2007-07-23 | 2012-04-11 | System of providing hygienic education information and method thereof | |
PT2650380E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
US20090198504A1 (en) * | 2008-02-05 | 2009-08-06 | Medavante, Inc. | Rater resource allocation systems and methods |
US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
WO2010003114A1 (fr) * | 2008-07-03 | 2010-01-07 | Neuera Pharmaceuticals, Inc. | Monoglycéride d'acétoacétate et dérivés pour le traitement de troubles neurologiques |
EP2387405A2 (fr) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzépine en tant qu'agent utilisé dans le traitement du cancer |
EP2360280A1 (fr) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Marqueur génétique pour le diagnostic de la démence doté de corps de Lewy |
US20120078521A1 (en) * | 2010-09-27 | 2012-03-29 | General Electric Company | Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data |
US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
RU2467680C1 (ru) * | 2011-10-04 | 2012-11-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ прогнозирования эффективности лечения больных ишемическим инсультом |
US10665328B2 (en) | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
US10658073B2 (en) | 2014-08-15 | 2020-05-19 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics |
EP3628315A1 (fr) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combinaison d'inhibiteur d'acétylcholinestérase et d'agoniste de récepteur de 5-ht4 comme agent neuroprotecteur dans le traitement de maladies neurodégénératives |
WO2020091375A2 (fr) * | 2018-10-29 | 2020-05-07 | 고려대학교 산학협력단 | Procédé et système de recommandation d'antidépresseur |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE262592T1 (de) * | 1992-10-13 | 2004-04-15 | Univ Duke | Verfahren zum nachweis der alzheimer krankheit |
CA2111503A1 (fr) * | 1993-12-15 | 1995-06-16 | Mcgill University | Polymorphisme de l'apolipoproteine e et maladie d'alzheimer |
FR2716894B1 (fr) * | 1994-03-07 | 1996-05-24 | Pasteur Institut | Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic. |
GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
GB9415073D0 (en) * | 1994-06-27 | 1994-09-14 | Smithkline Beecham Plc | Novel method |
GB9414624D0 (en) * | 1994-07-20 | 1994-09-07 | Smithkline Beecham Plc | Novel method |
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
-
1996
- 1996-12-16 US US08/766,975 patent/US6022683A/en not_active Expired - Lifetime
-
1997
- 1997-12-16 CA CA002275504A patent/CA2275504C/fr not_active Expired - Fee Related
- 1997-12-16 WO PCT/IB1997/001648 patent/WO1998027227A2/fr active IP Right Grant
- 1997-12-16 EP EP97952129A patent/EP0948647B1/fr not_active Expired - Lifetime
- 1997-12-16 AU AU56757/98A patent/AU745073B2/en not_active Ceased
- 1997-12-16 JP JP52750798A patent/JP2001524809A/ja not_active Withdrawn
- 1997-12-16 WO PCT/IB1997/001641 patent/WO1998027226A2/fr active IP Right Grant
- 1997-12-16 AU AU55717/98A patent/AU5571798A/en not_active Withdrawn
- 1997-12-16 AT AT97952129T patent/ATE269978T1/de not_active IP Right Cessation
- 1997-12-16 CA CA2275404A patent/CA2275404C/fr not_active Expired - Fee Related
- 1997-12-16 DE DE69729654T patent/DE69729654T2/de not_active Expired - Lifetime
- 1997-12-16 DE DE69729473T patent/DE69729473T2/de not_active Expired - Lifetime
- 1997-12-16 EP EP97953011A patent/EP0946753B1/fr not_active Expired - Lifetime
-
2000
- 2000-02-08 US US09/500,162 patent/US7001736B1/en not_active Expired - Fee Related
-
2009
- 2009-05-07 JP JP2009113073A patent/JP5202429B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-23 JP JP2012117411A patent/JP2012152229A/ja active Pending
- 2012-12-17 JP JP2012274378A patent/JP2013059347A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998027227B1 (fr) | Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux | |
Parker Jr et al. | Cytochrome oxidase deficiency in Alzheimer's disease | |
Prasher et al. | Molecular mapping of Alzheimer‐type dementia in Down's syndrome | |
WO1998027227A3 (fr) | Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux | |
WO1998027226B1 (fr) | Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique | |
EP0764914A3 (fr) | Procédé pour l'allocation de lits dans une station intensive de pédiatrie et pour l'évaluation de la qualité des soins | |
CA2188933A1 (fr) | Polymorphisme de l'apolipoproteine e et traitement de la maladie d'alzheimer | |
EP1521083A3 (fr) | Procédé pour le diagnostic et la caractérisation de l'attaque cérébrale | |
Chu et al. | Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease | |
EP1361229A3 (fr) | Utilisation de la Tyrosine Kinase (PYK2) pour la production d'anticorps | |
EP2397492A3 (fr) | Mutants d'angiogenine dans la sclérose amyotrophique laterale | |
AU2002237296A1 (en) | Conformationally abnormal forms of tau proteins and specific antibodies thereto | |
WO2002089657A3 (fr) | Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation | |
Zhang et al. | Evidence for the early onset of gingival inflammation following short‐term plaque accumulation | |
EP2644588A3 (fr) | Biomarqueurs pour le diagnostic de la sclérose en plaques et procédés associés | |
AU8969098A (en) | Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53 | |
EP1434053A4 (fr) | Reactif pour detecter un facteur de risque de la maladie d'alzheimer, necessaire de detection a cet effet, et procede de detection du facteur de risque de la maladie d'alzheimer au moyen de ce necessaire | |
Bouhouche et al. | Autosomal recessive mutilating sensory neuropathy with spastic paraplegia maps to chromosome 5p15. 31–14.1 | |
Reinhardt et al. | Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease | |
IL123834A0 (en) | Diagnostic method and kit for determining rh blood group genotype | |
CA2251744A1 (fr) | Procedes pour identifier la predisposition a l'osteoarthrose par un genotype recepteur de la vitamine d | |
AU6823600A (en) | Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease | |
AU1153300A (en) | Methods of diagnosing or prognosing alzheimer's disease | |
AU2904197A (en) | Diagnostic method and apparatus based on polymorphism in an IL-6 gene | |
JP2007500005A5 (fr) |